Strategy reduced nephropathy risky by 21% in patients with type 2 diabetes, study finds. Intensive glucose control with gliclazide (modified release) and other agents reduced the risk of nephropathy ...

Please provide your email address to receive an email when new articles are posted on . Using intensive blood pressure control in patients with stages 4 to 5 chronic kidney disease may delay the onset ...

Two studies provide additional support for lowering systolic blood pressure to an intensive goal of 120 mmHg – far below the standard guidelines of 140 mmHg – to reduce the risk of heart disease in ...

This carefully designed meta-analysis combined results from 5 recent clinical trials to shed further light on the confusing question of whether intensive glycemic control reduces the risk for ...

Intensive blood pressure control to a target of less than 120 mm Hg was not associated with a reduction of cerebral perfusion compared with a standard target of less than 140 mm Hg in a substudy of ...

(HealthDay News) — During long-term follow-up, the impact of a 4-year period of intensive glycemic control has a neutral effect on death and nonfatal cardiovascular events, according to a study ...

Researchers have projected that aggressively lowering blood pressure could help prevent more than 100,000 deaths in the U.S. each year. "The public health impact of adopting intensive treatment in the ...

SAN FRANCISCO, CA—In the SPRINT trial, patients who were treated to an intensive versus standard blood pressure goal had a lower risk of developing LV conduction disease, which hasn’t been considered ...

Please provide your email address to receive an email when new articles are posted on . In patients who had endovascular thrombectomy for acute ischemic stroke with large-vessel occlusion, intensive ...

Patients with advanced CKD have not been well-represented in trials evaluating intensive blood pressure control. Intensive blood pressure control to a systolic blood pressure less than 120 mm Hg may ...

The belief that the lower the glucose level the better in patients with type 2 diabetes who are at a high risk for MI or stroke has been called into question by an ongoing NIH-supported trial.

For nondiabetic patients with hypertension and a high cardiovascular risk, intensive lowering of blood pressure is associated with an expected drop in NT-proBNP but also a modest increase in ...